ArticleFrontiers in pharmacology2025

Systematic bioinformatics analysis identifies shikonin as a novel mTOR pathway inhibitor in triple-negative breast cancer progression.

Wenna Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.